MD Anderson and CureVac Enter Strategic Collaboration to Develop Novel Cancer Vaccines
April 17, 2024
April 17, 2024
HOUSTON, Texas, April 17 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 16, 2024:
* * *
Aligning complementary expertise, collaboration aims to develop off-the-shelf mRNA-based cancer vaccines for select hematologic and solid cancers
* * *
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mR . . .
* * *
Aligning complementary expertise, collaboration aims to develop off-the-shelf mRNA-based cancer vaccines for select hematologic and solid cancers
* * *
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mR . . .